For critical care AI tools, the key to adoption is not just accuracy but seamless integration. A "zero-click" approach that automatically processes scans and delivers results without adding steps to a clinician's workflow is paramount for buy-in.
To gain physician trust, AI companies must move beyond proving their algorithm is accurate. The gold standard is large-scale clinical evidence demonstrating tangible improvements in patient outcomes, treatment rates, and decision-making speed.
Instead of focusing only on physicians, Brainomix positions its AI as a value-add for the entire stroke treatment ecosystem. By helping increase the use of existing drugs and devices, they create strategic alignment with powerful pharma and med device partners.
The transition from academia to entrepreneurship is most successful when the focus shifts from pure science or technology to solving a tangible, pre-existing clinical problem. This ensures market interest, clinical adoption, and ultimately, patient impact from the outset.
A successful MedTech platform can be a blueprint for expansion. By identifying new disease areas with similar core problems (e.g., imaging-based diagnosis delays), a company can replicate its proven strategies for product development, evidence generation, and partnerships.
A common clinical need doesn't mean a one-size-fits-all commercial strategy. To scale globally, companies must appreciate the technical, clinical, and commercial differences in each healthcare system and invest in local resources to navigate them successfully.
A MedTech startup's initial go-to-market may be hospital-by-hospital sales. However, after building a robust evidence base of clinical and economic impact, the sales focus can shift to enterprise-level deals with regional or national healthcare systems, accelerating growth.